Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05022784 · ClinicalTrials.gov registry record
Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 1,798
- Enrollment target
NCT05022784 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,798 participants.
The verdict
NCT05022784 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 1,798 participants
- Enrollment target
Study Summary
This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: * Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients. * Understanding characteristics of patients within each nintedanib adherence trajectory among IPF patients.
Interventions
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,798 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2021-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05022784
The ClinicalTrials.gov registry entry for NCT05022784 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,798 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nintedanib is the first listed.
NCT05022784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05022784 about?
NCT05022784 is a clinical study titled "Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients". This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: * Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients. * Understanding characteristics of patients withi...
What is the current status of trial NCT05022784?
This trial is currently completed. The enrollment target is 1,798 participants. The study started on 2021-08-23. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT05022784?
The interventions under investigation include: Nintedanib (DRUG).
Who is sponsoring clinical trial NCT05022784?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.